CNCE News
Archived Headlines
- Concert Pharmaceuticals prices upsized IPO at $14, the high end of the range 02/13/14
- 9 US IPOs planned for the week of Feb 10 02/10/14
- US IPO Recap: Revance jumps 68% in ten-IPO week 02/10/14
- Biotech Concert Pharmaceuticals sets terms for $65 million IPO 02/03/14
- US IPO Recap: Group of energy-related IPOs comes up dry 01/21/14
See more
Feeling cramped? Muscle spasm biotech Flex Pharma sets terms for $60 million IPO
Flex Pharma, which is developing dietary supplements for the treatment of muscle cramps and spasms, announced terms for its IPO on Tuesday. The Boston, MA-based company plans to raise $60 million by offering 4.6 million shares at a price range of $12 to $14. At...read more
Kidney failure biotech Proteon Therapeutics sets terms for $61 million IPO
Proteon Therapeutics, a biotech developing a recombinant protein for patients undergoing surgery for kidney failure, announced terms for its IPO on Tuesday. The Waltham, MA-based company plans to raise $61 million by offering 4.7 million shares at a price range...read more
US IPO Recap: Wave goodbye to the biotech wave as tech prepares to take over
Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more
Health IPOs down 1% and housing IPOs trade up after heavy discount
The week’s five health sector IPOs have produced lackluster returns; together they are down 1% on average from their IPO prices. Amedica (AMDA), which creates improved spine, hip and joint replacements, dropped 6% today after pricing at the largest...read more